The specific features of hypertension and the choice of treatment policy in old women


Cite item

Full Text

Abstract

The paper discusses the specific features of the structure and function of the cardiovascular system and cardiovascular diseases, which depend on the age and hormonal status of women. Despite common principles in the antihypertensive treatment of male and female hypertensive patients, the latter have higher rates of adverse reactions from some medications, on the one hand, and special indications for the use of drugs, such as diuretics, on the other hand.

Full Text

Особенности течения артериальной гипертонии и выбор тактики терапии у женщин старшего возраста. - Аннотация. В работе обсуждаются особенности строения и функционирования сердечно-сосудистой системы и сердечно-сосудистых заболеваний, которые зависят от возраста и гормонального статуса у женщин. Несмотря на общность принципов антигипертензивной терапии у больных артериальной гипертонией у мужчин и женщин, для последних характерны, с одной стороны, более высокая распространенность побочных эффектов некоторых препаратов, с другой - наличие особых показаний к приему препаратов таких групп, как диуретики.
×

References

  1. Population ageing and development 2009, WHO Department of economic and social affairs, population division. Available at www.un.org/esa/population/publications/ageing/ageing2009.htm.
  2. Оганов Р.Г., Масленникова Г.Я. Гендерные различия кардиоваскулярной патологии. Кардиоваск тер и проф 2012; 11: 101-104.
  3. Mosca L., Banka C.L., Benjamin E.J. et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. Circulation 2007; 115: 1481-1501.
  4. Mosca L., Benjamin E.J., Berra K., Bezanson J.L. et al. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women - 2011 Update: A Guideline From the American Heart Association. Circulation 2011; 123: 1243-1262.
  5. Collins P., Rosano G., Casey C. et al. Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologist and gynaecologist. Eur Heart J 2007; 28: 2028-2024.
  6. Чазова И.Е., Сметник В.П., Балан В.Е. и др. Ведение женщин с сердечно-сосудистым риском в пери- и постменопаузе: консенсус российских кардиологов и гинекологов. Consilium Medicum 2008; 6: 5-18.
  7. Brown M.A., Chang R.J. Polycystic Ovary Syndrome: Clinical and Imaging Features. Ultrasound Q 2007; 23 (4): 233-238.
  8. Беляков Н.А., Сеидов Г.Б., Чубриева С.Ю., Глухов Н.В. Метаболические нарушения при синдроме поликистозных яичников у женщин репродуктивного возраста. В кн.: Метаболический сидром у женщин (патофизиология и клиника). СПб.: Издательский дом СПбМАПО 2005: 121-206.
  9. Chasan-Taber L., Willett W.C., Manson J.A.E. et al. Prospective Study of Oral Contraceptives and Hypertension Among Women in the United States. Circulation 1996; 94: 483-489.
  10. Kittner S.J., Stern B.J., Feeser B.R. et al. Pregnancy and the risk of stroke. N Engl J Med 1996; 335: 768 -774.
  11. Любченко Н.В. Отдаленные результаты гистерэктомии, произведенной в репродуктивном возрасте и коррекция с помощью ЗГТ: Дис. ... канд. мед. наук. М 2000; 197.
  12. Luoto R., Kaprio J., Reunanen A., Rutanen E.M. Cardiovascular morbidity in ration to ovarian function after hysterectomy. Obstet Gynecol 1995; 85 (4): 515-522.
  13. Howard B.V., Kuller L., Langer R. et al. Risk after cardiovascular disease by hysterectomy status, with or without oophorectomy. The Women's Health Initiative Observation Study. Circulation 2005; 111 (2): 1462-1470.
  14. Подзолков В.И., Брагина А.Е., Никитина Т.И., Подзолкова Н.М. Гистерэктомия как звено сердечно-сосудистого континуума. Кардиоваск тер и проф 2010; 3: 73-79.
  15. Oparil S., Miller A.P. Gender and blood pressure. J Clin Hypertens 2005; 7: 300-309.
  16. Ashraf M.S., Vongpatanasin W. Estrogen and hypertension. Curr Hypertens Rep 2006; 8: 368-376.
  17. Reckelhoff J.F. Gender differences in the regulation of blood pressure. Hypertension 2001; 37: 1199-1208.
  18. Подзолков В.И., Брагина А.Е., Родионова Ю.Н., Панферова Е.К. Гендерные особенности ренин-ангиотензин-альдостероновой системы у пациентов с артериальной гипертонией. Рациональная фармакотерапия в кардиологии. 2010 ; 6 (3): С.306-310.
  19. Подзолков В.И., Брагина А.Е., Родионова Ю.Н. Гендерные особенности концентрации лептина и внутрипочечной гемодинамики у больных эссенциальной артериальной гипертензией и ожирением. Системные гипертензии 2011; 2: 42-46.
  20. Janssen I., Powell L.H., Kazlauskaite R., Dugan S.A. Testosterone and Visceral Fat in Midlife Women: The Study of Women's Health Across the Nation (SWAN) Fat Patterning Study. Obesity 2010; 18: 604-610.
  21. Маслова Н.П., Баранова Е.И. Гипертоническая болезнь у женщин. СПб: Издательство СПбГМУ 2000; 214.
  22. Hermida R.C., Ayala D.E., Mojón A. et al. Differences Between Men and Women in Ambulatory Blood Pressure Thresholds for Diagnosis of Hypertension Based on Cardiovascular Outcomes Chronobiology International, Early Online: 2012: 1-12.
  23. Подзолков В.И., Брагина А.Е., Панферова Е.К. Состояние вегетативного статуса и его взаимосвязь с гуморальными факторами у женщин в перименопаузе. Системные гипертензии. 2010; 4: 62-67.
  24. Smulyan H., Asmar R.G., Rudnicki A. et al. Comparative effects of aging in men and women on the properties of the arterial tree. J Am Coll Cardiol 2001; 37: 1374-1380.
  25. Safar M.E., Smulyan H. Hypertension in women. Am J Hypertens 2004; 17: 82-87.
  26. Rossi P., Francès Y., Kingwell B.A., Ahimastos A.A. Gender differences in artery wall biomechanical properties throughout life. J Hypertens 2011; 29 (6): 1023-1033.
  27. Leonetti G., Cuspidi C., Facchini M. et al. Is systolic pressure a better target for antihypertensive treatment than diastolic pressure? J Hypertens 2000; 18 (Suppl. 3): 13-20.
  28. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152 (1): 56-64.
  29. Rothwell P.M. Limitation of the usual blood pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375 (9718): 938-948.
  30. Мамедов М.Н., Оганов Р.Г. Эпидемиологические аспекты метаболического синдрома. Кардиология 2004; 9: 15.
  31. Кисляк О.А., Стародубов А.В., Хаутиева Ф.М., Копелев А.А. Инфаркт миокарда у женщин с избыточной массой тела и ожирением. Consilium Medicum 2010; 12 (10): 26-31.
  32. Levitzky Y.S., Pencina M.J., D'Agostino R.B. et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol 2008; 51 (3): 264-270.
  33. Pyörälä K., Lehto S., De Bacquer D. et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetologia 2004; 47 (7): 1257-1265.
  34. Mucha L., Stephenson J., Morandi N., Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. Gend Med 2006; 3: 279-291.
  35. Perk J., De Backer G., Gohlke H. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701.
  36. Подзолков В.И., Брагина А.Е., Родионова Ю.Н., Панферова Е.К. Артериальная гипертензия у женщин. Есть ли основания для особой тактики лечения? Consilium Medicum 2009; 11(5): 49-54.
  37. Hayward C.S., Kalnins W.V., Kelly R.P. Gender-related differences in left ventricular chamber function. Cardiovasc Res 2001; 49 (2): 340-350.
  38. Hammond I.W., Devereux R.B., Alderman M.H. et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7: 639-650.
  39. Kannel W.B. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens 1991; 9 (Suppl 2): S3-S9.
  40. Os I., Oparil S., Gerdts E. et al. Essential hypertension in women. Blood Press 2004; 13: 272-278.
  41. Lloyd-Jones D.M., Larson M.G., Leip E.P. et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068-3072.
  42. Chung A.K., Das S.R., Leonard D. et al. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study. Circulation 2006; 113 (12): 1597-1604.
  43. Regitz-Zagrosek V., Brokat S., Tschope C. Role of gender in heart failure with normal left ventricular ejection fraction. Prog Cardiovasc Dis 2007; 49 (4): 241-251.
  44. Фомина И.Г., Брагина А.Е., Гайдамакина Н.Е., Салимжанова Ю.Н. Почечная гемодинамика и клубочковая фильтрация у больных гипертонической болезнью в возрасте 40-60 лет. Рацион тер в кардиол 2007; 5: 69-72.
  45. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
  46. Lloyd-Jones D.M., Evans J.C., Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294: 466-472.
  47. Чазова И.Е., Фомин В.В., Разуваева М.А., Вигдорчик А.В. Эпидемическая характеристика резистентной и неконтролируемой артериальной гипертонии РЕГАТА-ПРИМА. Системные гипертензии 2010; 3: 34-41.
  48. Оганов Р.Г., Ольбинская Л.И., Смулевич А.Б. и др. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология 2004; 1: 48-54.
  49. Mosca L., Hammond G., Mochari-Greenberger H. et al. Fifteen-Year Trends in Awareness of Heart Disease in Women Results of a 2012 American Heart Association National Survey. Circulation. published online February 19, 2013; available at http://circ.ahajournals.org/content/early/2013/02/19/CIR.0b013e318287cf2f
  50. La Puerta P., L'Italien G.J. Awareness, treatment, and control of systolic blood pressure in the United States. Am J Hypertens 1999; 12 (Pt 2): 92A.
  51. Seeland U., Regitz-Zagrosek V. Sex and gender differences in cardiovascular drug therapy. Handb Exp Pharmacol 2012; 214: 211-236.
  52. Raz L., Miller V.M. Considerations of sex and gender differences in preclinical and clinical trials. In: Regitz-Zagrosek V. (ed). Sex and gender differences in pharmacology. Heidelberg: Springer 2012.
  53. Blauwet L.A., Redberg R.F. The role of sex-specific results reporting in cardiovascular disease. Cardiol Rev 2007; 15 (6): 275-278.
  54. Tipnis S.R., Hooper N.M., Hyde R. et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275 (33): 238-243.
  55. Spoletini I., Vitale C., Malorni W., Rosano G.M.C. Sex differences in drug effects: interaction with sex hormones in adult life. In: Regitz-Zagrosek V. (ed). Sex and gender differences in pharmacology. Heidelberg: Springer 2012.
  56. Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009; 76: 215-228.
  57. Lee S.Y., Oh S.J., Yun K.U. et al. Expression of hepatic and ovarian cytochrome P450 during estrous cycle in rats. Arch Toxicol 2012; 86: 75-85.
  58. Lewis C.E., Grandits G.A., Flack J. et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Arch Intern Med 1996; 156: 377-385.
  59. Martin R.M., Biswas P.N., Freemantle S.N. et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998; 46: 505-511.
  60. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 2006; 5: 425-438.
  61. Lonn E., Roccaforte R., Yi Q. et al. Effects of long-term therapy with ramipril in high risk women. J Am Coll Cardiol 2002; 40: 693-702.
  62. Dahlof B., Dereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
  63. Mackay F.J., Pearce G.L., Mann R.D. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 1999; 47: 111-114.
  64. Strocchi E., Malini P.L., Valtancoli G. et al. Cough during treatment with angiotensin-converting enzyme inhibitors. Analysis of predisposing factors. Drug Invest 1992; 4: 69-72.
  65. Vaclavic J., Sedlac R., Jarlovsky J. et al. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial. Biomed Pap Med Fac Univ Palasky Olomouc Czech Repub 2012; 7: 1-7.
  66. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
  67. Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
  68. Jochmann N., Stangl K., Garbe E. et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005; 26: 1585-1595.
  69. MERIT-HF Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
  70. Packer M., Bristow M.R., Cohn J.N. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
  71. Simon T., Mary-Krause M., Funck-Brentano C., Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001; 103: 375-380.
  72. Ghali J.K., Pina I.L., Gottlieb S.S. et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002; 105: 1585-1591.
  73. Labbe L., Sirois C., Pilote S. et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000; 10: 425-438.
  74. Luzier A.B., Killian A., Wilton J.H. et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999; 66: 594-601.
  75. Kendall M.J., Quarterman C.P., Jack D.B., Beeley L. Metoprolol pharmacokinetics and the oral contraceptive pill. Br J Clin Pharmacol 1982; 14: 120-122.
  76. Thawornkaiwong A., Preawnim S., Wattanapermpool J. Upregulation of b1-adrenergic receptors in ovariectomized rat hearts. Life Sci 2003; 72: 1813-1824.
  77. Cotreau M.M., von Moltke L.L., Greenblatt D.J. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005; 44: 33-60.
  78. Krecic-Shepard M.E., Park K., Barnas C. et al. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000; 68: 130-142.
  79. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001; 2: 349-351.
  80. Wassertheil-Smoller S., Anderson G., Psaty B. M. et al. Hypertension and its treatment in postmenopausal women: baseline data from the Womenȼs Health Initiative. Hypertension 2000; 36: 780-789.
  81. ALLHAT Collaborative Research Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2000; 288: 2981-297.
  82. Rosenthal T., Oparil S. Hypertension in women. J Hypertens 2000; 14 (10-11): 691-704.
  83. Felson D.T., Sloutskis D., Anderson J.J. et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA 1991; 265 (3): 370-373.
  84. Schoofs M.W., van der Klift M., Hofman A. et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139: 476-482.
  85. Calhoun D.A., Oparil S. Gender and blood pressure. In: Hypertension primer. Izzo J.L., Black H.R. (eds). Dallas 2003: 253-257.
  86. Werner D., Werner U., Meybaum A. et al. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet 2008; 47: 323-332.
  87. Cerrutti J.A., Quaglia N.B., Brandoni A., Torres A.M. Effects of gender on the pharmacokinetics of drugs secreted by the renal organic anions transport systems in the rat. Pharmacol Res 2002; 45: 107-112.
  88. Brandoni A., Villar S.R., Torres A.M. Gender-related differences in the pharmacodynamics of furosemide in rats. Pharmacology 2004; 70: 107-112.
  89. Werner U., Werner D., Heinbuchner S. et al. Gender is an important determinant of the disposition of the loop diuretic torasemide. J Clin Pharmacol 2010; 50: 160-168.
  90. Chen Z., Vaughn D.A., Fanestil D.D. Influence of gender on renal thiazide diuretic receptor density and response. J Am Soc Nephrol 1994; 5: 1112-1119.
  91. Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 2005; 46: 758-765.
  92. Baguet J.P., Robitail S., Boyer L. et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducting blood pressure. Am J Cradiovasc Drugs 2005; 5 (2): 131-140.
  93. Чазова И.Е., Мычка В.Б. Окончательные результаты программы МИНОТАВР (пациенты с Метаболическим сИНдрОмом - эффекТивность и переносимость Арифона ретард В лечении аРтериальной гипертонии). Consilium medicum 2006; 8 (11): 11-15.
  94. Кобалава Ж.Д., Котовская Ю.В., Верещагина Г.Н. и др. Эффективность и переносимость индапамида при лечении артериальной гипертонии у больных пожилого возраста (результаты многоцентрового открытого несравнительного исследования в рамках Российской научно-практической программы АРГУС). Кардиология 2002; 7: 25-35.
  95. Сайгитов Р.Т., Глезер М.Г. Применение индапамида с контролируемым высвобождением у больных с артериальной гипертензией: метаанализ и сопоставление результатов российских и зарубежных открытых исследований. Пробл женск здор 2009; 4: 5-16.
  96. Gosse P., Sheridan D. J., Zannad F. et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465-1475.
  97. Marre M., Puig J.G., Kokot F. еt al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens 2004; 22: 1613-1622.
  98. London G., Asmar R., Schmieder R., Calvo C. Antihypertensive efficacy of Indapamide SR vs candesartan and amlodipine in hypertensive patients in isolated hypertensive patients. Am J Hypertens 2004; 17 (5): 183А.
  99. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomized double-blind studies. Drug Saf 2001; 24 (15): 1155-1165.
  100. Kuo S.W., Pei-Dee, Hung Y.J. et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens 2003; 16 (8): 623-628.
  101. Tran K., Ho C., Noorani H.Z. et al. Thiazide diuretics as first-line treatment for hypertension: meta-analysis and economic evaluation. Health Thecnology Assessment (HTA) Database, 2007. http://cadth.ca/en/products/health-technology-assessment/ publication/776.
  102. Beckett N.S., Peters R., Fletcher A.E. et al. Treatment of hypertension in patients 80 years of age or older. N Engl JMed 2008; 358: 1887-1898.
  103. Подзолков В.И., Можарова Л.Г., Хомицкая Ю.В. Менопаузальный метаболический синдром после гистерэктомии. Кардиоваск тер и проф 2005; 4: 76-81.
  104. Van Wijk B.L., Klungel O.H., Heerdink E.R., de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2006; 40 (1): 15-20.
  105. Глезер М.Г., Сайгитов Р.Т. Сравнительный анализ эффективности диуретиков в терапии артериальной гипертонии у женщин. Результаты исследования АФИНА. Пробл женск здор 2009; 2: 5-16.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies